Pfizer (NYSE:PFE) revealed that its COVID-19 drug Paxlovid retained in vitro efficacy against the omicron SARS-CoV-2 variant.
The company said that the research indicates that the drug can potentially maintain plasma concentrates “many-fold” times higher than the level needed to prevent replication of the highly transmissible variant.
“These data suggest that our oral COVID-19 therapy can be an important and effective tool in our continued battle against this devastating virus and current variants of concern,” said Dr. Mikael Dolsten, chief scientific officer at Pfizer, in a statement.
Demand for Paxlovid, which FDA authorized in late December, has far exceeded supply.
In January, the White House announced that the federal government would buy 20 million courses of Paxlovid — twice as much as initially planned.
Paxlovid combines two antivirals — nirmatrelvir and ritonavir.
In November 2021, Pfizer also announced a license agreement w…